Zach Hornby, Boundless Bio CEO

Bound­less Bio snags $100M to en­ter clin­ic and fight can­cer by tar­get­ing cir­cu­lar DNA bits

Bound­less Bio raised $100 mil­lion in a Se­ries C round, the San Diego biotech said Tues­day, as it brings its un­usu­al ap­proach to fight­ing can­cer in­to the clin­ic.

Since its found­ing in 2018, Bound­less has been re­search­ing ways to tar­get can­cer cells that have lit­tle cir­cu­lar bits of DNA float­ing out­side their chro­mo­somes. Based on re­search by the biotech’s sci­en­tif­ic co-founder Paul Mis­chel, these bizarre cir­cles of DNA aren’t mere­ly cel­lu­lar de­bris but a cul­prit of can­cer growth and re­sis­tance. Bound­less’s lead drug can­di­date aims to kill these can­cer cells by ex­ploit­ing a spe­cial vul­ner­a­bil­i­ty in them, with Bound­less dos­ing the first pa­tient ear­li­er this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.